FindTrial
Sign In

the application of Remazolam in children undergoing sedation

the application of Remazolam in children undergoing sedation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044246
Enrollment
Unknown
Registered
2021-03-12
Start date
2021-03-20
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

children sedation

Interventions

Remimazolam Group and Dexmedetomidine Group:Remimazolam intravenously versus Dexmedetomidine intranasally
Propofol group:Propofol intravenously

Sponsors

Maternal & Child Health Care Hospital of Huai'an City
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.The diagnostic and therapeutic workes to be performed under sedation include CT, echocardiography, MRI, hearing screening, etc. 2.aged younger than 14 years.

Exclusion criteria

Exclusion criteria: 1. The child had upper respiratory tract infection Within 2 weeks and abnormal respiratory development; 2. Children underwent sedation anesthesia within 48 hours; 3. The Children had neuropsychiatric disease; 4. Severe anemia, abnormal liver and kidney function; 5. Severe Cardiovascular Malformation; 6. Parents who refuse intravenous injections.

Design outcomes

Primary

MeasureTime frame
The induction time;wake-up time;the success rate of sedation;Hemoglobin oxygen saturation (SPO2), heart rate (HR), respiratory rate (R);side effects;—

Countries

China

Contacts

Public ContactHaikou Yang

Maternal & Child Health Care Hospital of Huai'an City

yanghaikou513@163.com+86 13952338436

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026